Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX)

Historical Holders from Q2 2019 to Q3 2025

Symbol
QNCX on Nasdaq
CUSIP
22053A107
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
56.3M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
11.8M
Holdings value
$19.2M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
45
Number of buys
22
Number of sells
-12
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Nantahala Capital Management, LLC 9.99% 0% $9.16M $1.39M 5.62M +17.9% Nantahala Capital Management, LLC Sep 30, 2025
Sofinnova Partners SAS 2.7% -54% $1.59M -$1.6M 1.2M -50% Sofinnova Capital VIII Mar 31, 2025

Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 11.8M $19.2M +$6.86M $1.63 45
2025 Q2 7.58M $12.5M +$3.95M $1.65 40
2025 Q1 5.23M $6.96M +$1.24M $1.33 35
2024 Q4 5.11M $9.55M +$494K $1.87 33
2024 Q3 5.19M $4.04M -$768K $0.78 32
2024 Q2 6.24M $4.67M -$801K $0.75 40
2024 Q1 7.26M $7.7M -$189K $1.06 43
2023 Q4 10.1K $10.7K $1.05 1
2023 Q3 7.48M $8.38M -$2.28M $1.12 38
2023 Q2 8.95M $13.5M +$1.95M $1.51 36
2023 Q1 7.62M $11.9M +$3.8M $1.56 38
2022 Q4 5.36M $3.41M -$3.3M $0.64 44
2022 Q3 9.09M $12.1M -$3.52M $1.33 50
2022 Q2 11M $24.5M -$25.4M $2.22 57
2022 Q1 11.4M $70.8M -$28M $6.19 79
2021 Q4 16.6M $210M -$233M $12.62 90
2021 Q3 19.2M $1.76B +$81.3M $91.66 130
2021 Q2 18.5M $982M -$6.01M $53.00 104
2021 Q1 18.7M $673M +$37.6M $36.03 89
2020 Q4 17.7M $491M +$26.9M $27.78 84
2020 Q3 16.5M $827M +$55.4M $50.00 83
2020 Q2 15.4M $715M +$185M $46.30 81
2020 Q1 11.5M $523M +$39.6M $45.61 65
2019 Q4 10.6M $594M +$91.8M $56.14 50
2019 Q3 5.84M $145M +$81.5M $24.93 40
2019 Q2 2.42M $103M +$103M $42.51 36